Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success
开发、展示和传播创新项目以实现转化成功
基本信息
- 批准号:10625364
- 负责人:
- 金额:$ 277.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-05 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAreaBioethicsBiotechnologyCessation of lifeClinicalClinical InvestigatorClinical Nursing ResearchClinical ResearchClinical SciencesCollaborationsCommunitiesCompetenceComplexConsultationsCreativenessDNA sequencingDataDedicationsDevelopmentDiagnosisDiseaseEducationElderlyElementsEnrollmentEnsureEnvironmentEvaluationFormulationFundingGenomeGrantHealthHealth PolicyHospitalsHumanHuman ResourcesImmunocompetenceIndividualInformed ConsentInfrastructureInstitutionKnowledgeLaboratoriesLeadershipMedicalMedicineMethodsModelingModificationMonitorNeighborhood Health CenterNew YorkNursesNursing ResearchOutcomeParticipantPatientsPennsylvaniaPharmacy facilityPhasePoliciesPopulationPreventionPublic HealthPublicationsReportingReproducibilityResearchResearch DesignResearch PersonnelResourcesScholars ProgramScienceScientistSpecial PopulationSpeedSurveysTimeTrainingTranslational ResearchTranslationsUniversitiesVisioncareerclinical centerclinical investigationcommunity engagementdesignempowermentexperiencehigh standardhuman diseaseimprovedinnovationmonoclonal antibody productionmultidisciplinarynext generationnovelnovel therapeuticsoutreachparticipant enrollmentparticipant safetypharmacokinetics and pharmacodynamicspractice-based research networkprogramsrecruitskillssuccesstherapeutic developmenttranslational scientist
项目摘要
The overall vision of the Rockefeller University Center for Clinical and Translational
Science (CCTS), supported by the CTSA program, is to develop, demonstrate, and disseminate
innovative programs so as to create a model clinical research enterprise built on rigor,
responsible and transparent reporting, and scientific integrity to empower translation of
paradigm-breaking discoveries into better human health. Our new initiatives are designed to: 1)
ensure that all of our studies set the highest standards; 2) ensure that our trainees have the team
science leadership skills needed for a career in translational science; and 3) enhance
scientific rigor, reproducibility, and reporting. These new areas build on the
infrastructure we have developed to integrate mechanistic science into community engagement,
reach out to basic scientists, speed the development of health- enhancing products, and create an
optimal training environment. Our specific aims are: 1. To provide a robust infrastructure to
support the conduct of clinical investigation at the highest levels of participant safety,
scientific rigor, bioethics, and regulatory compliance. We will enhance our multidisciplinary
Translational Research Navigation (TRN) Program and our collaboration with Clinical Directors
Network (CDN), a Practice Based Research Network of Community Health Centers, to ensure that our
studies meet the highest standards of design, feasibility, method validity, and transparent
reporting, supporting our active participation in the CTSA Trial Innovation Network. 2. To ensure
that every discovery at Rockefeller has the best chance of improving human health. We will enhance
our robust pipeline of programs to support basic and clinical investigators move their
paradigm-breaking discoveries into new therapeutics by leveraging the resources of the
Tri-Institutional Therapeutic Development Institute, the Robertson Therapeutic Development Fund,
and the University affiliated biotechnology company, Bridge Medicines .3. To educate the entire
research workforce team in conducting translational research at the highest levels of participant
safety, scientific rigor, bioethics, and regulatory compliance. We will further enhance the
multidisciplinary team science emphasis of our educational programs for KL2 Clinical Scholars,
Clinical Research Nurses, basic scientists, and community clinicians, with a focus on our new
Team Science Leadership training with the CTSA Hubs at Yale, University of
Pennsylvania, and Columbia. 4. To study and improve the clinical research enterprise both at
Rockefeller and nationally. We will continue to use the CCTS as a laboratory for investigating the
clinical research enterprise itself and methods to improve it, including obtaining outcome data
from research participants, enhancing rigor, reproducibility and reporting, speeding the evaluation
of novel therapeutics via in-house formulation, and creating 'super teams' of CTSA Hubs to
disseminate our model of community engagement harnessing basic mechanistic studies to
address community-identified health needs. We will disseminate the results throughout the CTSA
consortium and scientific community by publications, presentations, and active participation in
CLIC and CD2H initiatives.
洛克菲勒大学临床和转化中心的总体愿景
科学 (CCTS) 在 CTSA 计划的支持下,旨在开发、展示和传播
创新方案,打造严谨的临床研究典范企业,
负责任和透明的报告以及科学诚信,以增强翻译能力
突破范式的发现可以改善人类健康。我们的新举措旨在:1)
确保我们所有的研究都设定最高标准; 2)确保我们的学员有团队
转化科学职业所需的科学领导技能; 3) 增强
科学严谨、可重复性和报告。这些新领域建立在
我们开发了将机械科学融入社区参与的基础设施,
接触基础科学家,加快开发增强健康的产品,并创建一个
最佳的训练环境。我们的具体目标是: 1. 提供强大的基础设施
支持在参与者安全的最高水平上进行临床研究,
科学严谨性、生物伦理学和法规遵从性。我们将加强我们的多学科
转化研究导航 (TRN) 计划以及我们与临床总监的合作
网络(CDN),一个基于实践的社区卫生中心研究网络,以确保我们的
研究符合设计、可行性、方法有效性和透明度的最高标准
报告,支持我们积极参与 CTSA 试验创新网络。 2. 确保
洛克菲勒的每一项发现都有改善人类健康的最佳机会。我们将加强
我们强大的计划管道支持基础和临床研究人员移动他们的
通过利用资源,突破范式地发现新疗法
三机构治疗发展研究所、罗伯逊治疗发展基金、
和大学附属生物技术公司 Bridge Medicines .3。为了教育全体
研究人员团队以最高水平的参与者进行转化研究
安全性、科学严谨性、生物伦理学和法规遵从性。我们将进一步加强
KL2 临床学者教育计划的多学科团队科学重点,
临床研究护士、基础科学家和社区临床医生,重点关注我们的新研究
耶鲁大学 CTSA 中心的团队科学领导力培训
宾夕法尼亚州和哥伦比亚州。 4、研究和完善临床研究事业
洛克菲勒和全国。我们将继续使用CCTS作为实验室来调查
临床研究企业本身及其改进方法,包括获取结果数据
来自研究参与者的意见,提高严谨性、可重复性和报告,加快评估速度
通过内部配方开发新疗法,并创建 CTSA 中心“超级团队”
利用基本机制研究传播我们的社区参与模型
满足社区确定的健康需求。我们将在整个 CTSA 中传播结果
联盟和科学界通过出版物、演讲和积极参与
CLIC 和 CD2H 倡议。
项目成果
期刊论文数量(175)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.
- DOI:10.1111/exd.13805
- 发表时间:2019-01
- 期刊:
- 影响因子:3.6
- 作者:Yan BY;Garcet S;Gulati N;Kiecker F;Fuentes-Duculan J;Gilleaudeau P;Sullivan-Whalen M;Shemer A;Mitsui H;Krueger JG
- 通讯作者:Krueger JG
New therapies for psoriasis and psoriatic arthritis.
- DOI:10.1097/bor.0000000000000274
- 发表时间:2016-05
- 期刊:
- 影响因子:5.1
- 作者:Ritchlin CT;Krueger JG
- 通讯作者:Krueger JG
A randomized clinical trial in vitamin D-deficient adults comparing replenishment with oral vitamin D3 with narrow-band UV type B light: effects on cholesterol and the transcriptional profiles of skin and blood.
- DOI:10.3945/ajcn.116.150367
- 发表时间:2017-05
- 期刊:
- 影响因子:0
- 作者:M. Ponda;Yupu Liang;Jaehwan Kim;R. Hutt;K. Dowd;P. Gilleaudeau;M. Sullivan-Whalen;Tori Rodrick;Dong Joo Kim;I. Barash;M. Lowes;J. Breslow
- 通讯作者:M. Ponda;Yupu Liang;Jaehwan Kim;R. Hutt;K. Dowd;P. Gilleaudeau;M. Sullivan-Whalen;Tori Rodrick;Dong Joo Kim;I. Barash;M. Lowes;J. Breslow
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence.
对有或没有可卡因依赖的人重复施用 Opra Kappa (LY2456302),一种新型、短效、选择性 KOP-r 拮抗剂。
- DOI:10.1038/npp.2017.205
- 发表时间:2018
- 期刊:
- 影响因子:0
- 作者:Reed,Brian;Butelman,EduardoR;Fry,RebeccaS;Kimani,Rachel;Kreek,MaryJeanne
- 通讯作者:Kreek,MaryJeanne
High-Titer Rheumatoid Arthritis Antibodies Preferentially Bind Fibrinogen Citrullinated by Peptidylarginine Deiminase 4.
- DOI:10.1002/art.40035
- 发表时间:2017-05
- 期刊:
- 影响因子:0
- 作者:Blachère NE;Parveen S;Frank MO;Dill BD;Molina H;Orange DE
- 通讯作者:Orange DE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Barry Coller其他文献
Barry Coller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Barry Coller', 18)}}的其他基金
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success
开发、展示和传播创新项目以实现转化成功
- 批准号:
10413256 - 财政年份:2016
- 资助金额:
$ 277.54万 - 项目类别:
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success
开发、展示和传播创新项目以实现转化成功
- 批准号:
10349629 - 财政年份:2016
- 资助金额:
$ 277.54万 - 项目类别:
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success
开发、展示和传播创新项目以实现转化成功
- 批准号:
9310443 - 财政年份:2016
- 资助金额:
$ 277.54万 - 项目类别:
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success
开发、展示和传播创新项目以实现转化成功
- 批准号:
9261077 - 财政年份:2016
- 资助金额:
$ 277.54万 - 项目类别:
TRANSFORMING TRANSLATIONAL SCIENCE AND EDUCATION TO BENEFIT HUMAN HEALTH
转变转化科学和教育以造福人类健康
- 批准号:
8365034 - 财政年份:2011
- 资助金额:
$ 277.54万 - 项目类别:
TRANSFORMING CLINICAL AND TRANSLATIONAL RESEARCH AND EDUCATION AT ROCKEFELLER
改变洛克菲勒的临床和转化研究与教育
- 批准号:
8173835 - 财政年份:2010
- 资助金额:
$ 277.54万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 277.54万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 277.54万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 277.54万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 277.54万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 277.54万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 277.54万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 277.54万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 277.54万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 277.54万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 277.54万 - 项目类别:
Grant-in-Aid for Early-Career Scientists